Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Bladder Cancer

imatinib mesylate has been researched along with Bladder Cancer in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Khalifa, SE1
Aigner, A; Bakowsky, U; Özcetin, A1
Cerullo, C; Fonte, C; Iori, A; Lunghi, A; Molinara, E; Neri, B; Pellegrini, E; Rediti, M1
Ayrton, J; Dezube, BJ; Kwak, E; Lyons, J; Mahadevan, D; Shapiro, GI; Yule, M1
Berginski, ME; Burridge, K; Cao, L; Chen, Z; Gomez, SM; Huang, C; Itano, M; Jacobson, K; Kapustina, M; Lessey, E; Li, J; Trepat, X; Truskey, G1
Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT1
Cheng, L; Eble, JN; Jones, TD; Koch, MO; Lin, H; Lopez-Beltran, A; MacLennan, GT; Nigro, K; Pan, CX; Papavero, V; Tretiakova, M; Yang, XJ1

Trials

1 trial(s) available for imatinib mesylate and Bladder Cancer

ArticleYear
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jan-01, Volume: 21, Issue:1

    Topics: Adult; Aged; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoindoles; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Urinary Bladder Neoplasms

2015

Other Studies

6 other study(ies) available for imatinib mesylate and Bladder Cancer

ArticleYear
Immunohistochemical expression of CD117/KIT, HER2, and Erβ in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    International urology and nephrology, 2023, Volume: 55, Issue:10

    Topics: Carcinoma, Transitional Cell; Egypt; Estrogen Receptor beta; Humans; Imatinib Mesylate; Schistosomiasis; Urinary Bladder Neoplasms

2023
A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, Volume: 85, Issue:3 Pt A

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Gelatin; Gelatin Sponge, Absorbable; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Mice; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2013
Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
    Anticancer research, 2014, Volume: 34, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Omentum; Peritoneal Neoplasms; Piperazines; Pyrimidines; Rectal Neoplasms; Urinary Bladder Neoplasms

2014
Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Actins; Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Movement; Cell Shape; Imatinib Mesylate; Microscopy, Interference; Myosins; Phenotype; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Rats; rhoA GTP-Binding Protein; Shear Strength; Stress, Mechanical; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms

2013
Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
    Cancer research, 2013, Mar-01, Volume: 73, Issue:5

    Topics: Antigens, Nuclear; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homologous Recombination; Humans; Imatinib Mesylate; Ku Autoantigen; Lapatinib; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Urinary Bladder Neoplasms

2013
c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2005, Volume: 18, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Small Cell; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms

2005